Anzeige
Meldung des Tages: Antimon Engpässe: Armory Mining wird zum strategischen Anker in der neuen Sicherheitsarchitektur

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
157,54 €
-1,26 €
-0,79%
12:43:45 Uhr
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 17,63: VJ92NK
Werbung

Biogen News

01.04.26 wallstreetONLINE Redaktion
Fetter Pharma-Deal: Aktie explodiert +135 % nach Übernahme – Biogen zahlt brutal drauf und fällt
Biogen greift tief in die Tasche. Während die Aktie der übernommenen Firma dreistellig explodiert, verliert die eigene Aktie – Zweifel am Deal bleiben.Biogen greift tief in die Tasche. ...
31.03.26 - Maximilian Berger
BIOGEN INC: Schwäche signa­li­siert Neubewertung
BIOGEN INC (WKN: 789617, ISIN: US09062X1037, Symbol: IDP) im Abwärtstrend. Warum Anleger jetzt genau hinsehen und Risiken abwägen sollten.
31.03.26 - GlobeNewswire
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-​approved in three indications, including two rare kidney diseases, ...
30.03.26 - GlobeNewswire
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and ...
28.03.26 - GlobeNewswire
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants ...
20.03.26 - PR Newswire
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Results from Real-​World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-​irmb) in the United States Presented at AD/PD™ 2026 PR Newswire
19.03.26 - GlobeNewswire
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Late-​breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted ...
11.03.26 - GlobeNewswire
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status ...
05.03.26 - GlobeNewswire
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate ...
04.03.26 - GlobeNewswire
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental ...
19.02.26 - dpa-AFX
Rückschlag für Alzheimer-Mittel Lecanemab von Eisai und Biogen
Für den Alzheimer-​Wirkstoff Lecanemab gibt es nach Ansicht eines entscheidenden Expertengremiums keinen belegten Zusatznutzen im Vergleich zu älteren ...
11.02.26 - GlobeNewswire
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair
06.02.26 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
04.02.26 - GlobeNewswire
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 ...
28.01.26 - GlobeNewswire
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin ...
25.01.26 - PR Newswire
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-​irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease ...
12.01.26 - GlobeNewswire
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-​treated ...
09.01.26 n-tv
Zollerleichterungen kommen: Mercosur-Deal könnte Fleisch, Obst und Kaffee günstiger machen
Zwischen Europa und den Mercosur-​Ländern Brasilien, Argentinien, Uruguay und Paraguay sollen Zölle abgebaut und der Handel ausgeweitet werden. Umweltschützer fürchten ...
22.12.25 - GlobeNewswire
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-...
06.12.25 wallstreetONLINE Redaktion
Gewinner der Börsengeschichte: +472.505 % seit dem IPO: Aus 1.000 wurden $4.725.050!
Die performenstärkste Aktie der letzten 25 Jahre ist nicht Monster Beverage, Altria oder Amphenol. Eine US-​Tech-Aktie ließ sie alle hinter sich. Seit dem Börsen­gang 1999 stieg der ...

Newssuche

Videos

newspaper
01.04.26
Saisonalitäten: DAS machst Du falsch!
Viele Trader landen irgendwann bei Saisonalitäten, ziehen diesen stark fundamental basierten Ansatz ... Mehr »